PNC-27
A 32-amino acid cancer research peptide containing a p53 HDM2-binding domain that selectively targets and destroys cancer cells by binding HDM2 on their membranes and inducing necrosis.
Community Rating
No ratings yet
Compound Profile
PNC-27
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. PNC-27 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Selectively targets cells expressing HDM2 on their membrane - which appears to be cancer-specific
- Induces necrosis (not apoptosis) in targeted cancer cells - physically disrupts the cancer cell membrane
- Demonstrated activity against pancreatic cancer, breast cancer, ovarian cancer, and leukemia cell lines in preclinical models
- PNC-27 is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Selectively targets cells expressing HDM2 on their membrane - which appears to be cancer-specific
- Induces necrosis (not apoptosis) in targeted cancer cells - physically disrupts the cancer cell membrane
- Demonstrated activity against pancreatic cancer, breast cancer, ovarian cancer, and leukemia cell lines in preclinical models
- Does not appear to interact with non-cancerous cells in research settings - potentially high therapeutic selectivity
In Plain English
Simple summaryPNC-27 is a 32-amino acid chimeric peptide composed of a segment of p53 (the tumor suppressor protein) fused to a membrane-penetrating sequence from HDM-2 (the MDM2 protein that regulates p53). The concept: normal cells display HDM-2 on their surface only minimally; cancer cells overexpress it. PNC-27 is designed to bind HDM-2 on the cancer cell surface and insert into the membrane via its penetrating sequence, causing a rapid lysis-like cell death called membranolysis -- distinct from apoptosis. In vitro studies show PNC-27 kills cancer cell lines without toxicity to normal cells. It was developed by Stuart Aaronson and colleagues and represents an interesting approach to tumor-selective killing.
- Selectively targets cells expressing HDM2 on their membrane - which appears to be cancer-specific
- Induces necrosis (not apoptosis) in targeted cancer cells - physically disrupts the cancer cell membrane
- Demonstrated activity against pancreatic cancer, breast cancer, ovarian cancer, and leukemia cell lines in preclinical models
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is PNC-27?
Tap any underlined term for an instant definition.
PNC-27 is a 32-amino acid peptide that has attracted significant interest in cancer biology research for its apparent ability to selectively kill cancer cells while leaving normal cells unaffected. The peptide was originally synthesised in the year 2000 as part of research into HIV/immunodeficiency, before its cancer-selective properties were identified.
The structure of PNC-27 incorporates the sequence of the p53 protein residues 12-26 (the region that interacts with HDM2, the human homologue of murine double minute 2) fused to a leader sequence that facilitates membrane interaction. This design was intended to disrupt the p53-HDM2 interaction inside cells, preventing HDM2-mediated p53 degradation and restoring p53's tumour-suppressive function. This mechanism has been widely studied, and compounds targeting the p53-HDM2 interface have been extensively investigated as anticancer agents.
However, PNC-27's cancer selectivity appears to stem from a different, more direct mechanism. Research demonstrated that HDM2 protein is expressed on the membrane surface of many cancer cells - not just intracellularly - and that PNC-27 binds to this membrane-expressed HDM2. This binding triggers pore formation in the cancer cell membrane, compromising its integrity and leading to necrotic cell death through ion flux disruption and loss of cellular contents.
The crucial observation is that non-cancerous cells do not express HDM2 on their surface membranes, explaining PNC-27's apparent selectivity. Normal cells express HDM2 primarily intracellularly, making them resistant to the membrane-disrupting mechanism. Cancer cells' aberrant membrane HDM2 expression appears to be a consequence of their transformed state, potentially reflecting a gain-of-function activity of oncogenic HDM2 overexpression.
The necrotic mode of cell death is mechanistically significant. Many cancer cells develop resistance to apoptosis - the programmed cell death pathway targeted by most conventional chemotherapy and many newer targeted therapies. By inducing physical membrane rupture rather than apoptosis, PNC-27 bypasses apoptosis resistance mechanisms, making it potentially relevant for treatment-resistant cancers. Published preclinical studies have demonstrated activity against pancreatic cancer, breast cancer, ovarian cancer, and haematological malignancies.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on PNC-27. See all Immune System peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
PNC-27 research doses are derived entirely from preclinical studies. No established human clinical dose exists.
In vitro: 2-10 microM concentration in cell culture studies In vivo preclinical: 1-5 mg/kg in rodent tumour models, administered intratumorally or systemically Research focus: cancer cell line sensitivity testing, selectivity studies, mechanism elucidation
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute PNC-27 with sterile water for injection or PBS. Administer by the route specified in the research protocol (intratumoral, IV, or SC). Given the intended anticancer mechanism, use in appropriate oncology research settings with relevant safety protocols.
What the research doesn't show
PNC-27's in vitro data is interesting but the compound has not advanced to human clinical trials. The membranolysis mechanism, while selective in cell culture conditions, needs extensive in vivo validation before its therapeutic potential can be assessed. The p53/MDM2 axis has been a major oncology drug target for decades -- the difficulty of translating selective cancer cell killing from lab to patient is well-documented in this space.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain PNC-27, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
PNC-27 has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: selectively targets cells expressing hdm2 on their membrane - which appears to be cancer-specific.
The most commonly reported side effect in research subjects is limited clinical data in humans - primarily preclinical evidence. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
FOXO4-DRI targets senescent cells rather than cancer cells but also uses a peptide-based selective killing approach. Conventional chemotherapy kills rapidly dividing cells indiscriminately. MDM2 inhibitors (nutlins, navtemadlin) target MDM2 intracellularly rather than at the cell surface. PNC-27's cell surface MDM2 targeting is mechanistically distinct from all of these.
Compare PNC-27 side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.